Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6806279 | 0.84 | KMT2A (0.54) | KMT2AMEN1ALDH1A1PTPN1MAPK1 | |
| SCHEMBL11807375 | 0.81 | KMT2A (0.51) | KMT2AMEN1ALDH1A1PTPN1MAPK1 | |
| SCHEMBL3404332 | 0.80 | KMT2A (0.50) | KMT2AMEN1ALDH1A1PTPN1MAPK1 | |
| SCHEMBL29255120 | 0.80 | KMT2A (0.50) | KMT2AMEN1ALDH1A1PTPN1MAPK1 | |
| SCHEMBL27842108 | 0.79 | KMT2A (0.49) | KMT2AMEN1ALDH1A1PTPN1MAPK1 | |
| SCHEMBL27842109 | 0.79 | KMT2A (0.49) | KMT2AMEN1ALDH1A1PTPN1MAPK1 | |
| Hydrochloric Acid SCHEMBL4228454 | 0.79 | KMT2A (0.49) | KMT2AMEN1ALDH1A1PTPN1MAPK1 | |
| SCHEMBL21782232 | 0.79 | ALDH1A1 (0.55) | KMT2AMEN1ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL11779839 | 0.78 | ALDH1A1 (0.58) | KMT2AMEN1ALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL1809268 | 0.78 | ALDH1A1 (0.58) | KMT2AMEN1ALDH1A1MAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2825528-B1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 2017-05-24 | — | — | EP | disclosed |
| US-8993614-B2 | Substituted pyrrolidine-2-carboxamides | F. HOFFMANN-LA ROCHE AG (CH) | 2015-03-31 | — | — | US | disclosed |
| EP-2825528-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | F. Hoffmann-La Roche AG (CH) | 2015-01-21 | — | — | EP | disclosed |
| WO-2013135648-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-09-19 | — | — | WO | disclosed |
| US-20130244958-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | HOFFMANN-LA ROCHE INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-7169803-B2 | N-substituted prodrugs of fluorooxindoles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| US-20050203089-A1 | N-substituted prodrugs of fluorooxindoles | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203089-A1 | N-substituted prodrugs of fluorooxindoles | KCNA5, KCNQ5, KCNQ2 | KMT2A 3047/4885MEN1 1213/4885ALDH1A1 2272/4885 |
| US-20130244958-A1 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES | CCNY, ARG2, RPS4Y1 | KMT2A 367/4885MEN1 2576/4885ALDH1A1 1924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.